Endometriosis affects a 10 % of @entity1 during their reproductive years. Unequoral statistics concerning the incidence of @entity1870 are not available although a combined occurrence of both diseases is found in a 20 % of cases. The risk that @entity5 arises from endometrioid tissue typical for @entity46 is between a 0.3-1 %. 75 % of these @entity5 are @entity43 in conjunction with pre-existing @entity43 ; less frequently extraovarian @entity5 are found. The development of @entity5 of @entity1870 is very rarely reported. In this report we present the case of a 35 year old @entity1 who suffered from both, @entity46 and @entity1870 and who underwent a therapy using @entity1176 analogues. After five months and before the completion of the therapy a hysterectomy with conservation of the ovaries was performed at the request of the @entity1 (carcinophobia). The histology confirmed the diagnosis of @entity1870 and demonstrated the unexpected finding of an @entity1204 . This latter arose from a complex atypical @entity1373 surrounded by hypoplastic endometrium. There is some evidence that suggests a slightly elevated risk of @entity5344 as well as haematological @entity5 amongst @entity1 with @entity46 . However, there does not appear to be an increased risk of @entity1204 . Adipositas leads to an increased risk for the development of @entity1204 due to the increased conversion of @entity251 to @entity1815 in fat. The peripheral synthesis of @entity1815 is unaffected by @entity4397 -therapy. A @entity1420 containing HRT should be added to a @entity4397 -therapy in overweight @entity1 to prevent the development of @entity1204 . In conclusion a careful indication has to be made for @entity4397 -therapy in overweight @entity1 and before and during the therapy high resolution ultrasound scan should be performed to evaluate the endometrium in those @entity1 .

[ @entity1204 using @entity1176 analogues therapy in XXXX ].

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian endometriosis', 'ovarian cancer'] @entity1204 :: ('MESH:D016889', 'Disease') :: ['endometrial carcinoma', 'endometrium carcinoma', 'endometrial hyperplasia and/or carcinoma'] @entity251 :: ('MESH:D013739', 'Chemical') :: ['testosterone'] @entity5344 :: ('MESH:D061325', 'Disease') :: ['breast and ovarian cancer'] @entity1420 :: ('MESH:D011374', 'Chemical') :: ['progesterone'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancy', 'malignancies'] @entity1870 :: ('MESH:D062788', 'Disease') :: ['adenomyosis'] @entity1373 :: ('MESH:D006965', 'Disease') :: ['hyperplasia'] @entity4397 :: ('CHEBI:63533', 'Chemical') :: ['GnRHa'] @entity46 :: ('MESH:D004715', 'Disease') :: ['endometriosis'] @entity1176 :: ('MESH:D007987', 'Chemical') :: ['GnRH'] @entity1815 :: ('MESH:D004970', 'Chemical') :: ['estrone']
@entity46 :: (MESH:D004715,Disease) :: ['endometriosis']
